Topics Include:
| Friday, 27 February 2026 | ||
| Time | Talk Title | Speaker |
| 07:00-08:00 | Industry Symposium: Sponsored by | Axel Hauschild |
| 08:00-09:00 | Clinical features of melanoma | Chairs: Dagmar Whitaker and Jessica Hassel |
| 08:00-08:20 | Lentigo maligna | Johann de Wet |
| 08:20-08:40 | Acral melanoma | Bianca Tod |
| 08:40-09:00 | Melanoma in SOC | Willie Visser |
| 09:00-09:50 | Sun protection and Vitamin D controversies | Chairs: Claus Garbe and Willie Visser |
| 09:00-09:15 | Why we don’t recommend routine Vitamin D supplementation in Germany? | Claus Garbe |
| 09:15-09:30 | Vitamin D and sun protection: an update | David Whiteman |
| 09:30-09:45 | Prevention is still better than cure | Dagmar Whitaker |
| 09:45-09:50 | Questions | |
| 09:50-10:15 | Tea Break | |
| 10:15-10:45 | Keynote lecture: Epidemiology of melanoma and Non-melanoma skin cancer | David Whiteman (Chair: Dagmar Whitaker) |
| 10:45-11:45 | Metastatic melanoma therapy | Chairs: Grant Mc Arthur and Sze Wai Chan |
| 10:45-11:05 | Target and Immunotherapy | Sze Wai Chan |
| 11:05-11:25 | Metastatic Melanoma: What are our options in 2025 | Grant Mc Arthur |
| 11:25-11:45 | Melanoma Brain Metastatic: What are our options | Jessica Hassel |
| 11:45-12:45 | Lunch Break | |
| 12:45-13:45 | The role of surgeons in the treatment of melanoma and non- melanoma skin cancer | Chairs: Merrick Ross and Mark Phipson |
| 12:45-13:00 | Management of high-risk cutaneous SCC | Johan De Wet |
| 13:00-13:15 | Is there still a role for surgery in stage III/IV melanoma patients? | Merrick Ross |
| 13:15-13:30 | Surgery will remain the gold standard | Mark Phipson |
| 13:30-13:45 | Long-Term Cure Rates of Keratinocyte Carcinomas treated with Mohs Micrographic Surgery in South Africa with a Five-Year+ Follow-Up | Pieter du Plessis |
| 13:45-14:15 | Keynote lecture: Anti-Cancer vaccines: The future of Melanoma and other Oncologic indications | Christoffer Gebhardt (Chair: Sze Wai Chan) |
| 14:15-15:00 | The role of the Pathologist in the diagnosis and management of malignant melanoma – from histology to genetic testing | Chairs: Johann Scneider and Christoffer Gebardt |
| 14:15-14:30 | Dilemmas and progress in the histological diagnosis of melanoma | Johann Schneider |
| 14:30-14:45 | Gold standards of genetic testing for melanoma | Christoffer Gebhardt |
| 14:45-15:00 | Molecular testing on melanoma – when to order, how to order and what’s available in SA | Chris Maske |
| 15:00-15:30 | Tea Break | |
| 15:30-17:00 | Parallel session 1: Dermatology: | |
| Dermoscopy workshop | Gary Levy / Rob Weiss | |
| 15:30-17:00 | Parallel session 2: Oncology: | |
| Treatment options for different stages of Melanoma | Chairs: Axel Hauschild, Sze Wai Chan | |
| Trials on Neoadjuvant ipilimumab/nivolumab for melanoma | Grant McArthur | |
| Is perioperative pembrolizumab an alternative to neoadjuvant ipi/nivo? | Axel Hauschild | |
| What is in the pipeline for the future? | Jessica Hassel | |
| 17:00-18:00 | Combined Session: Choosing the correct treatment | Chairs: Grant Mc Arthur and Dagmar Whitaker |
| 17:00-17:20 | Current European Guidelines on adjuvant treatment | Claus Garbe |
| 17:20-17:40 | How do I select the right patient for the best treatment option | Grant McArthur |
| 17:40-18:00 | When should we consider adjuvant radiation for melanoma | Henriette Burger |
| 18:00-18:30 | Melanoma Society meeting – meet the EXCO/become involved! | |
| 18:30 | Welcome reception in Exhibition Area | |
| Saturday, 28 February 2026 | ||
| 08:00-09:00 | Industry Symposium – Sponsored by | |
| 09:00-10:00 | Guideline changes in the treatment of Melanoma and Non-Melanoma Skin Cancers and rare tumours | Chairs: Jessica Hassel and Willie Visser |
| 09:00-09:20 | What is new for rare skin cancers? | Jessica Hassel |
| 09:20-09:40 | BCC, CSCC and MCC guidelines | Johann de Wet |
| 09:40-10:00 | Adjuvant Radiation for CSCC/BCC | Mariza Tunmer |
| 10:00-10:30 | Keynote Lecture: Immune Checkpoint Inhibition for non-Melanoma skin cancers: An Ongoing Revolution | Axel Hauschild (Chair: Sze Wai Chan) |
| 10:30-11:00 | Tea Break | |
| 11:00-12:00 | Interdisciplinary case discussions: Melanoma | Chairs: Merrick Ross and Willie Visser |
| 11:00-11:15 | Case 1: Multimodality treatment utilized in a patient with stage IV BRAF mutated Melanoma | Andre Vos |
| 11:15-11:30 | Case 2 | Pieter du Plessis |
| 11:30-11:45 | Case 3 | Merrick Ross |
| 11:45-12:00 | Case 4 | Mariza Tunmer |
| 12:00-13:00 | Interdisciplinary case discussions: Non-melanoma skin cancer | Chairs: Merrick Ross and Willie Visser |
| 12:00-12:15 | Case 1: Skin cancer in patients with Albinism | Daudi Mavura |
| 12:15-12:30 | Case 2: Squamous cell carcinoma following skin bleaching | Fatimata Ly |
| 12:30-12:45 | Case 3: DSFP | Vanessa Kriek |
| 12:45-13:00 | Case 4: Metastatic squamous cell carcinoma in patient with heart transplant | Redmund Nel |
| 13:00-14:00 | Lunch Break | |
| 14:00-14:30 | Keynote Lecture: How to avoid overtreatment of High-risk melanomas? | Merrick Ross Chair: Willie Visser |
| 14:30-15:00 | Parallel session 1: Oncobeta Parallel session 2: Foto Finder – Latest Updates in Digital Follow up & AI | Chair: Mariza Tunmer Chair: Dagmar Whitaker |
| 14:30-15:00 | Listen to the patient | Chair: Willie Visser |
| Patient with Albinism | ||
| Patient with Xeroderma pigmentosa | ||
| 15:30-16:30 | Ethics session | Chairs: Dagmar Whitaker and Sze Wai Chan |
| 15:30-15:45 | Access to new cancer treatment in resource poor countries | Lidija Kandolf |
| 15:45-16:00 | Skin cancer in South Africa – a funder perspective | Noluthando Nematswerani |
| 16:00-16:30 | Is it time to look at dignity to die and not only dignity to Hive? | Joseph Ramondo |
| 16:30 | Closing | |